|Bid||0.00 x 1300|
|Ask||0.00 x 900|
|Day's Range||175.53 - 176.75|
|52 Week Range||139.51 - 179.84|
|PE Ratio (TTM)||62.07|
|Earnings Date||Oct 25, 2018|
|Forward Dividend & Yield||1.88 (1.08%)|
|1y Target Est||184.60|
NEW YORK, Sept. 21, 2018-- The following statement is being issued by Levi & Korsinsky, LLP:. Levi & Korsinsky, LLP announces that investigations have commenced on behalf of shareholders of the following ...
September 20, 2018 - Stryker (SYK) announced that it will host a conference call on Thursday, October 25, 2018 at 4:30 p.m., Eastern Time, to discuss the Company`s operating results for the quarter ended September 30, 2018 and provide an operational update. To participate in the conference call dial (844) 826-0610 (domestic) or (973) 453-3249 (international) and be prepared to provide conference ID number 9086309 to the operator. To hear this recording, you may dial (855) 859-2056 (domestic) or (404) 537-3406 (international) and enter conference ID number 9086309.
So far in 2018, Thermo Fisher Scientific (TMO) stock has generated double-digit returns for investors. Boosted by its strong financial performance, it’s risen from $192.98 on January 2 to its current level of $240 in September.
Thermo Fisher Scientific (TMO) is a leading provider of analytical instruments, equipment, reagents, and consumables. Thermo Fisher Scientific generated total revenue of $6.08 billion in the second quarter compared to $4.99 billion in the comparable period of 2017. Thermo Fisher generates revenue from product sales and services.
The healthcare industry is watching the Trump presidency closely. President Trump's promise to repeal and replace Obamacare hit repeated stumbling blocks in Congress. Despite the uncertainty surrounding these efforts to overhaul the nation's healthcare system, a number of healthcare stocks rose dramatically throughout 2017.
NEW YORK, Sept. 14, 2018-- The following statement is being issued by Levi & Korsinsky, LLP:. Levi & Korsinsky, LLP announces that investigations have commenced on behalf of shareholders of the following ...
Today, Zimmer Biomet Holdings (ZBH) is trading at $128.82, which represents a ~2.08% rise from yesterday’s close of $126.19.
Thermo Fisher Scientific (TMO) announced on September 7, 2018, that the company offers end-to-end analytical solutions that comply with cannabis testing standards as defined by Health Canada.
After looking at Stryker Corporation’s (NYSE:SYK) latest earnings update (30 June 2018), I found it helpful to revisit the company’s performance in the past couple of years and compare thisRead More...
NEW YORK, Sept. 12, 2018-- The following statement is being issued by Levi & Korsinsky, LLP:. To: All Persons or Entities who purchased Invuity, Inc. stock prior to September 11, 2018. You are hereby notified ...
The stock market is a running milestone. We're currently in the longest-ever bull market - a fact that became official on Wednesday, Aug. 22, when it became 3,453 days old. Some have shrugged off the milestone; others, in evaluating stock picks, have been vexed by it. Scott Sadler, Founder and President at Boardwalk Capital Management, is part of the camp that understands a bull market has no specific time limit. He explains, "Bull markets don't die of old age, so the ticking clock isn't all that relevant. What is relevant is what conditions will make the bull market die. And usually, that has to do with tightening monetary policy." The other camp understands all things are cyclical, and further believes the growth boom is nearly out of gas. Reality is somewhere in the middle. The Federal Reserve is chasing a moving target; inflation isn't rampant yet, but it is clearly brewing. But the rekindled economy may not be strong enough to withstand more aggressive hawkishness. It's time for investors to at least start thinking defensively. This means owning stocks that can perform during the latter stages of a bull market but hold up should things turn sour. Here are 12 top stock picks to that end. SEE ALSO: 16 High-Yielding Monthly Dividend Stocks to Buy
This deal will have Stryker acquiring Invuity for $7.40 per share. Stryker notes that it will be using cash to fund its purchase of IVTY stock. A subsidiary of Stryker will be using this cash to make a tender offer for all outstanding shares of IVTY stock.
SAN DIEGO , Sept. 11, 2018 /PRNewswire/ -- Shareholder rights law firm Johnson Fistel, LLP has launched an investigation into whether the board members of Invuity, Inc. (NASDAQ: IVTY) ("Invuity") ...
September 11, 2018 - Stryker (SYK) announced today a definitive agreement to acquire all the issued and outstanding shares of common stock of Invuity, Inc. (IVTY) for $7.40 per share, or a total equity value of approximately $190 million. Founded in 2004, and headquartered in San Francisco, California, Invuity`s portfolio of innovative products is highly complementary to the Surgical portfolio of Stryker`s Instruments business. Under the terms of the agreement, Stryker will commence a tender offer for all outstanding shares of common stock of Invuity for $7.40 per share, in cash. The boards of directors of both Stryker and Invuity have approved the transaction.
Invuity, Inc. (IVTY), a leading medical technology company focused on advanced surgical devices to enable better visualization, today announced it has entered into a definitive agreement with Stryker Corporation (SYK), pursuant to which Stryker will acquire all of the outstanding shares of Invuity for $7.40 per share in cash, implying a total equity value of approximately $190 million. "The combination of Stryker's established leadership in minimal access surgery paired with Invuity’s suite of enabling visualization and surgical devices should facilitate better patient outcomes and operating room efficiencies in women’s health, general surgery, electrophysiology and orthopedics," said Scott Flora, Invuity’s Interim Chief Executive Officer.
In September, of the 17 analysts covering Intuitive Surgical (ISRG), 11 have given its stock “buy” or higher ratings, five have given it “hold” ratings, and one has given it a “sell” rating.
WILMINGTON, Del., Sept. 06, 2018-- Rigrodsky & Long, P.A.:. Do you own shares of K2M Group Holdings, Inc.? Did you purchase any of your shares prior to August 30, 2018?
This translated into a net income per share of $2.25 in the second quarter. Its net income per share was $2.01 in the second quarter of 2017. In July, Intuitive Surgical received FDA clearance for the marketing of its da Vinci EndoWrist Stapler, SureForm 60, which is a single-use stapling instrument with particular uses in bariatric procedures.
Intuitive Surgical (ISRG) incurred a total cost of sales of $277 million in the second quarter compared to $228.7 million in the second quarter of 2017. This increase came from a higher product cost of sales, which increased from $184.7 million in the second quarter of 2017 to $228.1 million in the second quarter of 2018.
NEW YORK, Sept. 05, 2018-- The following statement is being issued by Levi & Korsinsky, LLP:. Levi & Korsinsky, LLP announces that investigations have commenced on behalf of shareholders of the following ...
When Stryker Corp. needed to fill some serious gaps in its spinal surgery devices business, the Fortune 500 med-tech behemoth turned to a small, but fast-growing firm in Leesburg: K2M Group Holdings Inc. And now, K2M's planned $1.4 billion sale to Kalamazoo, Michigan-based Stryker could help the local company grow even faster as well, analysts say. Stryker (NYSE: SYK) is likely to invest more research and development funding in K2M (NASDAQ: KTWO) to push forward its products, even as it saves on manufacturing plant consolidation and other overlapping costs. “We could potentially see even stronger growth from a KTWO product portfolio under Stryker’s roof,” said Joshua Jennings, managing director and senior research analyst with New York-based Cowen and Co. LLC. The deal, expected to close late in the fourth quarter, would make K2M a wholly owned subsidiary of Stryker, and K2M CEO Eric Major president of Stryker’s spine division.
How Do Abiomed’s Valuations Look in September? Wall Street analysts estimate Abiomed (ABMD) will report 29.9% growth in revenues to ~$771.0 million in 2019 as compared to $593.7 million in 2018. The earnings per share are expected to be $4.66 in 2019.